Search PubMed⌕ Search

Biomedical subjects

R J Nash

Publications and source records attributed to R J Nash.

46 records · Page 3Linked to original sources
PubMed1984

An overview of side effects and long-term experience with nomifensine from United States clinical trials.

During the clinical development of nomifensine maleate (Merital), 1319 depressed patients received nomifensine (average doses of 150 mg/day) in 4-6 week trials; treatment was continued for at least 2 months in 170 patients and at least 6 months in 53. Comparison data were provided by 593 patients who received placebo and 612 given the tricyclic antidepressant imipramine HCl (average doses of 150 mg/day). The relationship of therapeutic gain to interfering side effects (the therapeutic index) was rated by the investigators and nomifensine received a more favorable therapeutic index rating than did imipramine. Side effect information was collected at each visit. Nomifensine produced less sedating, anticholinergic, and other discomforting side effects than imipramine and was able to sustain clinical benefit with minimal side effects in patients treated up to 6 months.

Adult↗
PubMed1979

Psychomotor changes during initial day of benzodiazepine medication.

1 The detracting psychomotor effects of diazepam (5 mg three times daily) and clobazam (an investigational 1,5-benzodiazepine) were compared with placebo effects over the course of the initial day of medication. Tests were administered at hourly intervals and the data were analyzed from the standpoint of contrasts at each session and from the standpoint of trends that accrued during the course of the day. 2 It is concluded that among normal volunteers diazepam 5 mg three times daily may be near the threshold for detracting psychomotor consequences during the initial day and that clobazam seems to be without detracting consequences and may have some enhancing effects.

Adult↗
PubMed1976

A comparison of the effect of imipramine, nomifensine, and placebo on the psychomotor performance of normal males.

Imipramine (50 mg), nomifensine (50 mg) or placebo was administered early morning, late morning, and mid-afternoon to normal volunteers. The program of hourly tests included: the Digit Symbol Substitution, Perceptual Reversal, Time Estimation Test, and Simple and Complex Continuous Performances tests both of which required recognition of briefly exposed letters of the alphabet. It was found that relative to placebo or nomifensine, imipramine had a clearly detracting effect on most of the tests. Drowsiness was reported more often in the imipramine group than in the placebo and nomifensine groups combined.

Adult↗
PubMedDate not supplied

Application of gradient-enhanced nuclear Overhauser effect spectroscopy GOESY) in the structure elucidation of plant secondary metabolites.

Gradient enhanced nuclear Overhauser effect spectroscopy (GOESY) has been applied in the structural elucidation of five plant secondary metabolites: eucalyptin, arctigenin, 5-geranyloxy-7-methoxycoumarin, 2,6-dihydroxy-4-methoxyisovalerophenone and N-feruloyltyramine. The importance and sensitivity of this technique in structure elucidation of plant secondary metabolites are discussed.

Anisoles↗
PubMedDate not supplied

Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease.

Dosage and tolerance are critical issues in successful drug therapy for patients with Alzheimer's disease (AD). A clear distinction among patient populations and AD patient subpopulations is necessary to ensure a thorough assessment of new central nervous system-active compounds. Phase I inpatient trials, in which tolerance and safety are evaluated under double-blind conditions in the target population, provide valuable information for use in planning multicenter outpatient trials. In similar studies, even those involving the elderly, tolerance and safety outcomes in healthy volunteers are not always predictable. An early trial of the effects of velnacrine in healthy, elderly, male volunteers was followed by a trial in the target population. A group of volunteers, aged 60 to 74 years who did not have AD, received 300 mg of velnacrine each day. This dosage was well tolerated for 28 days. Diarrhea, generally of moderate severity, was the only reported adverse effect. No subjects were required to discontinue taking velnacrine. In contrast, a similar trial showed a dosage of 300 mg of velnacrine each day intolerable among patients with AD. Adverse reactions to dosages greater than 225 mg/day included dizziness, fainting, nausea and/or vomiting, headache, and severe diarrhea. A velnacrine dosage of 225 mg/day appeared to be safe and well tolerated in a small population of healthy patients with AD. Based on the inpatient experience with AD subjects, a maximum dose of 225 mg/day was adopted for outpatient studies. Although factors that may contribute to drug sensitivity in patients with AD vary beyond conclusive parameters, the observed sensitivity within the target AD group may indicate a safety/tolerance study as a worthwhile antecedent to multicenter efficacy trials.

Administration, Oral↗